4.7 Article

miR-133a represses tumour growth and metastasis in colorectal cancer by targeting LIM and SH3 protein 1 and inhibiting the MAPK pathway

Journal

EUROPEAN JOURNAL OF CANCER
Volume 49, Issue 18, Pages 3924-3935

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2013.07.149

Keywords

Colorectal carcinoma; Tumour metastasis; Signal pathway; MicroRNAs

Categories

Funding

  1. National Natural Science Foundation of China [30901792, 81272762, 81201635]
  2. Research Foundation of Guangzhou Medical College [2010C33]
  3. Key Project of Affiliated Tumor Hospital of Guangzhou Medical College [2011-yz-05]
  4. Guangdong Natural Science Funds for Distinguished Young Scholar [S20120011334]
  5. Guangdong Natural Science Foundation [S2012040006418]

Ask authors/readers for more resources

In recent studies of microRNA expression, miR-133a deregulation was identified in colorectal carcinoma (CRC). However, the mechanisms underlying the pathogenesis and progression of CRC are poorly understood. We found that miR-133a expression was usually down-regulated in CRC cell lines and tissue specimens. Ectopic miR-133a expression inhibited cell proliferation and cell migration. Stable overexpression of miR-133a was sufficient to suppress tumour growth and intrahepatic and pulmonary metastasis in vivo. Additional studies showed that miR-133a can target the 30 untranslated region (3'UTR) of LIM and SH3 protein 1 (LASP1) mRNA and suppress the expression of LASP1, which we identified in previous studies as a CRC-associated protein. In contrast to the phenotypes induced by miR-133a restoration, LASP1-induced cell proliferation and migration rescued miR-133a-mediated biological behaviours, as did LASP1 overexpression. Investigations of possible mechanisms underlying these behaviours revealed that miR-133a modulates the expression of key cellular molecules and participates in the MAPK pathway by inhibiting phosphorylation of ERK and MEK. miR-133a may play a key role in CRC genesis and metastasis, which suggests its potential role in the molecular therapy of cancer. (C) 2013 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available